Notes / Company Nectar Lifesciences Ltd. NECLIFE BSE 532649 ISIN INE023H01027 Pharmaceuticals Fundamentals Market cap₹240 cr P/E-0.68× ROE0.00% Debt / equity0.61 52-week range 9.30 — 28.25 The timeline — 1 note on Nectar Lifesciences Ltd. May 2026 25 May 26 · 1:23 PM IST Brief Brief Nectar Lifesciences sets May 30 for FY26 results The board will meet on May 30, 2026, to approve audited financial results for the year ended March 31, 2026. Verify on exchange BSE filings for NECLIFE NSE filings for NECLIFE